Protagonist Therapeutics
Develops orally-stable peptides to treat diseases that are currently addressed by injectable antibodies. Learn more
Launch date
Employees
Market cap
€2.5b
Enterprise valuation
€2.0b (Public information from Sep 2024)
Share price
$45.92 PTGX
Newark California (HQ)
Authorizing premium user...